Feds put Teva's Copaxone, Azilect marketing under FCA microscope

Federal prosecutors are eyeing Teva Pharmaceutical Industries ($TEVA) for potential marketing violations. As Bloomberg reports, the Justice Department has demanded documents related to Teva's marketing of its multiple sclerosis drug Copaxone and its Parkinson's disease treatment Azilect. The government is investigating "potential violations of the False Claims Act," the company said in its annual filing with the Securities and Exchange Commission. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.